Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Knowledge Synthesis Grant

University of Ottawa

$100,000.00

Guideline development for treatment of HIV/AIDS and TB co-infection

EF 2009-10

Résumé
HIV infection is the greatest single risk factor for developing tuberculosis. In Africa, tuberculosis(TB) is often the first manifestation of HIV infection, and it is the leading cause of death among HIV infected patients. The lifetime risk for a TB infected person to develop clinical TB is about 5 to 10% in an HIV negative person and 50% in an HIV positive person. TB leads to death within months in most of those co-infected if left untreated. The recent emergence of multi-drug resistant (MDR) TB and extensively-drug resistant (XDR) TB has further complicated public health efforts at treating and preventing co-infections. Guidelines on the management of co-infected patients are disparate. World Health Organization (WHO) guidelines are broad and often not clinically relevant in extremely resource-limited settings. As a local response, African countries are developing national and regional guidelines that may or may not be evidence-based. Several countries recommend against providing duel care, while others may prefer TB treatment as the primary disease followed by HIV/AIDS care. With serious drug interactions and adverse events likely to occur, optimal treatment strategies are necessary to prevent serious clinical events or death. Our proposal aims to answer important questions about the efficacy and safety of HIV/TB combined treatment and to determine the unanswered role of a preventive therapy.
Programme
Knowledge Synthesis Grant
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
193255
Name
Mills Edward J
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Clinical
Prcname2
Knowledge Synthesis Grant
Projecttitle
Guideline development for treatment of HIV/AIDS and TB co-infection
Programtype2
Operating Grants
Orgnameinp2
University of Ottawa
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Knowledge Synthesis Grant
Keyworddelim
Co-Infections; Hiv/Aids; Tuberculosis
Abstract
HIV infection is the greatest single risk factor for developing tuberculosis. In Africa, tuberculosis(TB) is often the first manifestation of HIV infection, and it is the leading cause of death among HIV infected patients. The lifetime risk for a TB infected person to develop clinical TB is about 5 to 10% in an HIV negative person and 50% in an HIV positive person. TB leads to death within months in most of those co-infected if left untreated. The recent emergence of multi-drug resistant (MDR) TB and extensively-drug resistant (XDR) TB has further complicated public health efforts at treating and preventing co-infections. Guidelines on the management of co-infected patients are disparate. World Health Organization (WHO) guidelines are broad and often not clinically relevant in extremely resource-limited settings. As a local response, African countries are developing national and regional guidelines that may or may not be evidence-based. Several countries recommend against providing duel care, while others may prefer TB treatment as the primary disease followed by HIV/AIDS care. With serious drug interactions and adverse events likely to occur, optimal treatment strategies are necessary to prevent serious clinical events or death. Our proposal aims to answer important questions about the efficacy and safety of HIV/TB combined treatment and to determine the unanswered role of a preventive therapy.
Competitiondate
200910
Approvedterm2
1 yr 0 mth
Pinamesdelim
Mills, Edward J; Montaner, Julio S
Approvedterm
1 an 0 mois
Cihrcontribution2
Science Policy 4~ $100,000~ $0~